Project description
Intelligent discovery platform for better drug development
New drug development and clinical trials takes about 15 years and costs on average EUR 2.3 billion with a success rate of around 12 %. EU funding has enabled InterAx Biotech to develop a systems biology and artificial intelligence-based platform for drug candidate selection with built-in in vivo predictability to dramatically reduce animal testing (60-80 %) and increase probability of success in clinical trials. Their custom-designed services focus on G-protein coupled receptors, which are targets of 40 % of existing drugs. Pharmaceutical and biotech companies can outsource critical stages in drug discovery at reduced expenses and shorter time to market (10 years) – a win-win for the companies as well as the consumers.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencescomputer and information sciencesartificial intelligence
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- social scienceseconomics and businessbusiness and managementbusiness models
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
5234 Villingen
Switzerland
See on map